Elucid Names Scott Huennekens Executive Chairman of the Board

April 25, 2023—Elucid, Inc., a provider of artificial intelligence (AI)–powered imaging analysis software to assess cardiovascular disease, announced that it has named Scott Huennekens Executive Chairman of its Board of Directors. Elucid is headquartered in Boston, Massachusetts.

According to Elucid, Huennekens has > 25 years of experience as a medtech CEO, chairperson, board member, entrepreneur, and investor. He has held leadership roles in > 20 startup, growth, and public companies with market valuations that have totaled > $20 billion, including eight initial public offerings (IPOs).

As President and CEO at Volcano Corporation, Huennekens guided the company to an IPO in 2006, prior to the company’s sale to Philips in 2015. He also served as President and CEO of Verb Surgical, a Google and J&J joint venture, and as President and CEO of Digirad Corporation, a coronary imaging solutions provider. His board leadership includes more than a dozen public and private companies.

Huennekens holds an MBA from Harvard University in Cambridge, Massachusetts, and a BS in business administration from the University of Southern California in Los Angeles, California.

Elucid CEO Blake Richards commented in the company’s press release, “There are few medtech leaders with Scott’s vast experience, and his particular expertise in technology characterizing vascular disease is perfectly aligned to Elucid’s mission. He has a proven track record in building innovative companies addressing large, unmet clinical needs. Having Scott join us as Executive Chairman at this phase in the company’s rapid growth will be invaluable toward achieving our mission of unprecedented precision health care to reduce deaths from heart attack and stroke.”

Also in the press release, Huennekens stated, “It is an honor to join Elucid as Chairman of the Board of Directors. Elucid technology is a powerful and proven tool designed to advance coronary artery disease risk prediction and management in the cardiology practice. Characterizing risk of heart attack and stroke is an unmet need, and Elucid technology has the potential to change the way we diagnose patients at risk to provide a new standard of care.”

Elucid’s plaque analysis software is powered by PlaqueIQ, an FDA-cleared CTA algorithm that objectively quantifies plaque morphology.

PlaqueIQ provides critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid plaque analysis software is available for commercial use in the United States, United Kingdom, European Union, and South Korea.

The company is also pursuing an indication for fractional flow reserve derived from CT (FFRCT) using PlaqueIQ technology to noninvasively measure coronary blockages and the extent of ischemia.